title: Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples.
abstract: BACKGROUND
  Antiretroviral drugs have been shown to reduce risk of mother-to-child transmission of human immunodeficiency virus (HIV) and are also widely used for post-exposure prophylaxis for parenteral and sexual exposures. Sexual transmission may be lower in couples in which one partner is infected with HIV and the other is not and the infected partner is on antiretroviral therapy (ART).
  
  
  OBJECTIVE
  To determine if ART use in an HIV-infected member of an HIV-discordant couple is associated with lower risk of HIV transmission to the uninfected partner compared to untreated discordant couples.
  
  
  METHODS
  We used standard Cochrane methods to search electronic databases and conference proceedings with relevant search terms without limits to language.
  
  
  METHODS
  Randomised controlled trials (RCT), cohort studies and case-control studies of HIV-discordant couples in which the HIV-infected member of the couple was being treated or not treated with ART DATA COLLECTION AND ANALYSIS: Abstracts of all trials identified by electronic or bibliographic scanning were examined independently by two authors. We initially identified 3,833 references and examined 87 in detail for study eligibility. Data were abstracted independently using a standardised abstraction form.
  
  
  RESULTS
  One RCT and nine observational studies were included in the review. These ten studies identified 2,112 episodes of HIV transmission, 1,016 among treated couples and 1,096 among untreated couples. The rate ratio for the single randomised controlled trial was 0.04 [95% CI 0.00, 0.27]. All index partners in this study had CD4 cell counts at baseline of 350-550 cells/µL. Similarly, the summary rate ratio for the nine observational studies was 0.58 [95% CI 0.35, 0.96], with substantial heterogeneity (I(2)=64%). After excluding two studies with inadequate person-time data, we estimated a summary rate ratio of 0.36 [95% CI 0.17, 0.75] with substantial heterogeneity (I(2)=62%). We also performed subgroup analyses among the observational studies to see if the effect of ART on prevention of HIV differed by the index partner's CD4 cell count. Among couples in which the infected partner had ≥350 CD4 cells/µL, we estimated a rate ratio of 0.12 [95% CI 0.01, 1.99]. In this subgroup, there were 247 transmissions in untreated couples and 30 in treated couples.
  
  
  CONCLUSIONS
  ART is a potent intervention for prevention of HIV in discordant couples in which the index partner has ≤550 CD4 cells/µL. A recent multicentre RCT confirms the suspected benefit seen in earlier observational studies and reported in more recent ones. Questions remain about durability of protection, the balance of benefits and adverse events associated with earlier therapy, long-term adherence and transmission of ART-resistant strains to partners. Resource limitations and implementation challenges must also be addressed.Counselling, support, and follow up, as well as mutual disclosure, may have a role in supporting adherence, so programmes should be designed with these components. In addition to ART provision, the operational aspects of delivering such programmes must be considered.
authors: Global Health Sciences, University of California, San Francisco, San Francisco, California, USA.
authors: Andrew
authors: A
authors: Anglemyer
authors: George W
authors: GW
authors: Rutherford
authors: Tara
authors: T
authors: Horvath
authors: Rachel C
authors: RC
authors: Baggaley
authors: Matthias
authors: M
authors: Egger
authors: Nandi
authors: N
authors: Siegfried
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission*; D018023:HIV Seronegativity; D006679:HIV Seropositivity / Q000188:drug therapy / Q000635:transmission; D059147:HIV Serosorting; D006801:Humans; D008297:Male; D012747:Sexual Partners
chemical_list: D019380:Anti-HIV Agents
references: Cochrane Database Syst Rev. 2011 Jul 06;(7):CD003510
references: 21735394
references: JAMA. 2008 Aug 6;300(5):540-9
references: 18677026
references: J Infect Dis. 2007 Dec 1;196(11):1629-36
references: 18008246
references: J Infect Dis. 2004 Sep 1;190(5):879-85
references: 15295691
references: BMJ. 2010 May 14;340:c2205
references: 20472675
references: Antivir Ther. 2011;16(7):1057-62
references: 22024521
references: J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):275-83
references: 11873077
references: Lancet. 2013 Oct 5;382(9899):1195-203
references: 23206835
references: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002835
references: 17253483
references: AIDS. 2011 Feb 20;25(4):473-7
references: 21160416
references: AIDS. 2009 Jul 17;23(11):1397-404
references: 19381076
references: AIDS. 2006 Jan 2;20(1):85-92
references: 16327323
references: Lancet. 2008 Jun 28;371(9631):2183-91
references: 18586173
references: Sex Transm Infect. 2011 Feb;87(1):17-21
references: 20643658
references: J Infect Dis. 2005 May 1;191(9):1403-9
references: 15809897
references: PLoS One. 2010 Jun 10;5(6):e11068
references: 20548786
references: J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):324-6
references: 17003695
references: BMJ. 2009 Apr 30;338:b1649
references: 19406887
references: HIV Med. 2009 Oct;10(9):548-54
references: 19515092
references: Lancet. 2010 Aug 14;376(9740):532-9
references: 20638713
references: Clin Infect Dis. 2010 May 15;50 Suppl 3:S96-101
references: 20397962
references: Cochrane Database Syst Rev. 2011 Aug 10;(8):CD009153
references: 21833973
references: AIDS. 2010 Mar 13;24(5):737-44
references: 20042848
references: BMJ. 2008 Apr 26;336(7650):924-6
references: 18436948
references: Lancet. 2010 Jun 12;375(9731):2092-8
references: 20537376
references: Clin Infect Dis. 2010 May 15;50 Suppl 3:S85-95
references: 20397961
references: Clin Infect Dis. 2010 Jan 1;50(1):98-105
references: 19951169
references: Arch Intern Med. 1994 Sep 12;154(17):1971-6
references: 8074601
references: BMJ. 2003 Jan 25;326(7382):219
references: 12543843
references: J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jan 1;17(1):42-5
references: 9436757
references: J Infect Dis. 2011 Dec 15;204(12):1918-26
references: 21990420
references: Lancet. 2009 Jan 3;373(9657):48-57
references: 19038438
references: Am J Epidemiol. 1997 Oct 15;146(8):655-61
references: 9345119
references: AIDS Res Hum Retroviruses. 2008 Jul;24(7):919-24
references: 18593343
references: Cochrane Database Syst Rev. 2011 May 11;(5):CD009153
references: 21563172
references: J Infect. 2006 Apr;52(4):290-3
references: 16038980
references: N Engl J Med. 2011 Aug 11;365(6):493-505
references: 21767103
references: Cochrane Database Syst Rev. 2012 Jul 11;(7):CD007189
references: 22786505
references: Lancet. 2001 Apr 14;357(9263):1149-53
references: 11323041
references: N Engl J Med. 2000 Mar 30;342(13):921-9
references: 10738050
references: J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):96-101
references: 16123689
references: J Acquir Immune Defic Syndr. 2010 Oct 1;55(2):232-238
references: 21423851
references: AIDS. 2009 Sep 24;23(15):2050-4
references: 19710596
references: AIDS. 2004 Jan 2;18(1):81-8
references: 15090833
references: Sex Transm Dis. 2008 Nov;35(11):912-5
references: 18607309
references: AIDS Res Hum Retroviruses. 2001 Jul 1;17(10):901-10
references: 11461676
references: Curr Opin HIV AIDS. 2010 Jul;5(4):277-82
references: 20543601
references: PLoS One. 2007 Dec 19;2(12):e1312
references: 18091987